KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).

Pascal Pujol, Lise Roca, Alain Lortholary, Christine Lasset, Louise Crivelli, Pascaline Berthet, Isabelle Tennevet, Thierry Petit, Nathalie Chabbert-Buffet, Paul Gesta, Claire Saule, Jean Chiesa, Tan Dat Nguyen, Audrey Mailliez, Nasrine Afdjei Callet, Catherine Noguès, Hélène Dreyfus, Capucine Delnatte, Fabienne Prieur, Laurence Gladieff, Olivier Ingster, Virginie Galibert, Jérôme Lemonnier, Suzette Delaloge

Eur J Cancer 231 116101

PMID41240533
PMCID-
DOI10.1016/j.ejca.2025.116101
发表日期2025-11-15
入排依据:The study is a randomized, placebo-controlled, Phase III trial with a drug intervention (letrozole) and an HR reported. However, the primary endpoint is the 5-year incidence of invasive breast cancer (a prevention outcome), not a time-to-event efficacy endpoint in the context of treating established malignancy (e.g., OS, PFS, DFS). The criteria require a primary/key secondary time-to-event efficacy endpoint for a drug intervention trial, which is not met here.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Women carrying a germline BRCA1 or BRCA2 mutation (gBRCAm) have a 70 % lifetime risk of breast cancer (BC). Aromatase inhibitors (AI) decrease BC incidence in high-risk populations but have not been specifically assessed in gBRCAm carriers. METHODS: LIBER was a randomized, double-blind, placebo-controlled, phase III trial. Post-menopausal women aged between 40 and 70 years carrying a gBRCAm were randomly allocated either 5 years of letrozole (2.5 mg/day) or placebo. Women with prior BC in remission for more than 5 years ago were eligible to assess the risk of second BC. Randomization was stratified by type of gBRCAm (BRCA1 versus BRCA2), previous bilateral oophorectomy, and prior BC. The primary endpoint was the 5-year incidence of invasive BC. Safety and quality of life were analyzed. RESULTS: Between 2008 and 2013, 170 women were randomized: 86 to placebo and 84 to letrozole. At 5 years, treatment adherence was 73.5 % with placebo and 76.7 % with letrozole. After a median follow-up of 72.7 months (95 % CI 71.5-78.5), the 5-year incidence of invasive BC was 13.1 % with placebo and 7.8 % with letrozole: hazard ratio, 0.70 (95 % CI 0.29-1.66), p = 0.416. Safety events and quality of life did not statistically differ in the arm. CONCLUSION: Due to the underpowered nature of the trial and the observed trend, it cannot be ruled out that using AI to prevent invasive breast cancer could be effective for BRCA1/2 carriers overall, or for specific subgroups within a larger sample size. Further randomised controlled trials are needed to determine the potential benefits of AI for gBRCA1/2m carriers.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。